Giselle Sholler: The FDA-ODAC said YES to DFMO!!

Quoting Giselle Sholler, Division Chief Pediatric Hematology, Oncology, BMT at Penn State Health Children’s Hospital, on LinkedIn:

”The FDA-ODAC said YES to DFMO!! After 13 years of preclinical and clinical research studying DFMO for neuroblastoma, today was culmination of so many years of work alongside Genevieve Bergendahl, Patrick Lacey, Meryl Witmer, William Ferguson and Jacqueline Kraveka. I am so grateful to have had an incredible team to walk with through this journey (and it has been quite a journey!). It has taken a village – our Beat Childhood Cancer Research Consortium, Team, the Beat Childhood Cancer Foundation, KC Pharma, US WorldMeds/Kristen Gullo, all the physicians, nurses, research teams, and most importantly the families who trusted us with the care of their children and enrolled on our studies. Because of them, we have hope that every child everywhere will now have access to DFMO!”

For the article click here.
Source: Giselle Sholler/LinkedIn